Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Plecanatide is indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adult patients.
Synergy Research Site, St-Romuald, Quebec, Canada
San Marcus Research Clinic, Inc., Miami, Florida, United States
Genoma Research Group, Inc., Miami, Florida, United States
South Medical Research Group, Inc., Miami, Florida, United States
Southwest Gastroenterology Assoc, Oak Lawn, Illinois, United States
Medex Healthcare Research, Inc., Chicago, Illinois, United States
Advance Medical Research Service Corp, Miami, Florida, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.